Alnylam Pharmaceuticals, Inc. (ALNY) CEO Yvonne Greenstreet on Q1 2022 Results - Earnings Call Transcript

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q1 2022 Earnings Conference Call April 28, 2022 8:30 AM ET

Company Participants

Christine Lindenboom - Senior Vice President of Investor Relations and Corporate Communications

Yvonne Greenstreet - Chief Executive Officer

Tolga Tanguler - Chief Commercial Officer

Pushkal Garg - Chief Medical Officer

Jeff Poulton - Chief Financial Officer

Conference Call Participants

David Lebowitz - Citigroup

Maury Raycroft - Jefferies

Salveen Richter - Goldman Sachs

Paul Matteis - Stifel

Matthew Harrison - Morgan Stanley

Ritu Baral - Cowen

Tazeen Ahmad - Bank of America

Gena Wang - Barclays

Anupam Rama - JPMorgan

Operator

Good day, and thank you for standing by. Welcome to the Alnylam Pharmaceuticals First Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised today’s conference may be recorded. [Operator Instructions]

I’d now like to hand the conference over to your host today, Christine Lindenboom, Senior Vice President of Investor Relations and Corporate Communications.

Christine Lindenboom

Good morning. I'm Christine Lindenboom, Senior Vice President of Investor Relations and Corporate Communications at Alnylam. With me today on the phone are Yvonne Greenstreet, Chief Executive Officer; Tolga Tanguler, Chief Commercial Officer; Pushkal Garg, Chief Medical Officer; and Jeff Poulton, Chief Financial Officer. Akshay Vaishnaw, President is unable to join the call today due to a personal conflict.

For those of you participating via conference call, the accompanying slides can be accessed by going to the Events section of the Investors page of our website, investors.alnylam.com/events. During today’s call is outlined on Slide 2, Yvonne will deliver introductory remarks and provide some general context. Tolga will provide an update on our global commercial progress. Pushkal will review recent clinical and preclinical updates; and Jeff will review our financials, followed by a summary of our upcoming milestones before we open the call for your questions.

I would like to remind you that this call will contain remarks concerning Alnylam’s future expectations, plans and prospects which constitute forward-looking statements for the purposes of the Safe Harbor provision under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in our most recently quarterly report on file with the SEC.